Issue
LncRNA NORAD targets miR-410-3p to regulate drug resistance sensitivity of osteosarcoma
Corresponding Author(s) : Guanlin Yang
Cellular and Molecular Biology,
Vol. 66 No. 3: Issue 3
Abstract
The current experiment was performed to investigate the effect of LncRNA NORAD on the sensitivity of miR-410-3p to drug resistance of osteosarcoma cells. The cisplatin-resistant cell line HOS/DDP was induced; si-NC, si-NORAD, miR-NC, miR-410-3p, pcDNA-NC, and pcDNA-NORAD were transfected into HOS/DDP cells, respectively; record as a si-NC group, si-NORAD group, miR-NC group, miR-410-3p group, pcDNA-NC group, pcDNA-NORAD group; si-NORAD was co-transfected into HOS/DDP cells with anti-miR-NC, anti-miR-410-3p, recorded as an anti-miR-NC+si-NORAD group and anti-miR-410-3p+si-NORAD group. Real-time quantitative PCR (RT-qPCR) was used to detect LncRNA NORAD, miR-410-3p and multidrug resistance protein 1 (MRP1) mRNA expression levels; Western blot was used to detect cyclin D1 (CyclinD1), MRP1, phosphorylated (p-p65), phosphorylated IкBα (p-IкBα) protein expression; cell counting kit 8 (CCK-8) was used to detect cell viability; dual luciferase report assay to detect targeting relationship between LncRNA NORAD and miR-410-3p. Compared with osteosarcoma cells HOS, the expression levels of LncRNA NORAD, MRP1 mRNA and protein in osteosarcoma resistant cells HOS/DDP were significantly increased, and miR-410-3p expression levels were significantly reduced (P<0.05). Low expression of NORAD or high expression of miR-410-3p, CyclinD1, MRP1 expression levels were significantly reduced, the cell survival rate was significantly reduced, and the half inhibitory concentration of cisplatin was significantly reduced (P<0.05). LncRNA NORAD targets and regulates miR-410-3p, and low expression of miR-410-3p can reverse the effects of low NORAD expression on HOS/DDP cell proliferation and cisplatin resistance. Low expressions of NORAD, p-p65, p-IкBα protein expression levels were significantly reduced; low expression of miR-410-3p could reverse the inhibitory effect of low NORAD expression on p-p65, p-IкBα protein expression. Inhibition of LncRNA NORAD expression can inhibit the proliferation of osteosarcoma HOS/DDP cells through targeted regulation of miR-410-3p, increasing its sensitivity to cisplatin, and it may be related to the NF-κB signaling pathway.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- Zhang Jianfeng, Liu Yunxia. New advances in chemotherapy for osteosarcoma. Zhejiang Clinic Med J 2018; 20 (8): 1464-1466.
- Chen Jinquan, Zhang. Research progress on the mechanisms of chemotherapy resistance of osteosarcoma. Chin J Bone Tumor Bone Dis 2017; 6 (12): 918-923.
- Yong Lei, Liu Xiaoguang. Research progress on the mechanism of osteosarcoma tolerance to cisplatin. Chin J Bone Tumor Bone Dis 2019, 8 (5): 41-46.
- Liu Yishu, Qu Guofan. Research progress on long-chain non-coding RNA in osteosarcoma. Pract Oncol J 2019; 23 (3): 266-270.
- Zhang J, Li XY, Hu P, Ding YS. LncRNA NORAD contributes to colorectal cancer progression by inhibition of miR-202-5p. Oncology Research Featuring Preclinic Clinic Cancer Therapeutic 2018; 26(9):1411-8.
- Zhou K, Ou Q, Wang G, Zhang W, Hao Y, Li W. High long non-coding RNA NORAD expression predicts poor prognosis and promotes breast cancer progression by regulating TGF-β pathway. Cancer Cell Int 2019;19(1):63.
- Gui Peng. Research progress on MiRNA's targeted regulation of drug resistance mechanism of osteosarcoma. Chin Cancer 2019; 28 (9): 694-698.
- Chen R, Li X, He B, Hu W. MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma. Mol Med Rep 2017; 15(3): 1326-1334.
- Zhao Zhenling, Shao Huanjun, Hao Lina. Effect of miR-410-3p on prostate cancer cell proliferation and apoptosis and its mechanism of action. Int J Urology Nephrol 2018; 38 (5): 754-758.
- Bai Guangjian, Han Zhitao, Liu Ge. Research progress on osteosarcoma related lncRNA. Chin J Clinic Oncology 2018; 45 (6): 297-300.
- Li Yuchun. Effect of long non-coding RNA H19 on cisplatin chemotherapy sensitivity of osteosarcoma and its mechanism of action. Chin J Gerontolog 2017; 37 (24): 6043-6046.
- Huo H, Tian J, Wang R, Li Y, Qu C, Wang N. Long non-coding RNA NORAD upregulate SIP1 expression to promote cell proliferation and invasion in cervical cancer. Biomed Pharmac. 2018; 106:1454-60.
- Li H, Wang X, Wen C, Huo Z, Wang W, Zhan Q, Cheng D, Chen H, Deng X, Peng C, Shen B. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. Mol Cancer 2017; 16(1):169.
- Tan BS, Yang MC, Singh S, Chou YC, Chen HY, Wang MY, Wang YC, Chen RH. LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. Oncogene 2019; 38(28): 5612-26.
- Wang C, Huang S, Rao S, Hu J, Zhang Y, Luo J, Wang H. Decreased expression of miR-410-3p correlates with poor prognosis and tumorigenesis in human glioma. Cancer Manag Res, 2019; 11(1): 10581-10592.
- Zhang YF, Yu Y, Song WZ, Zhang RM, Jin S, Bai JW, Kang HB, Wang X, Cao XC. miR-410-3p suppresses breast cancer progression by targeting Snail. Oncol Rep, 2016; 36(1): 480-486.
- Zhang L, Pang Y, Cui X, Jia W, Cui W, Liu Y, Liu C, Li F. MicroRNA-410-3p upregulation suppresses proliferation, invasion and migration, and promotes apoptosis in rhabdomyosarcoma cells. Oncol Lett, 2019, 18(1): 936-943.
- Xiong J, Wang D, Wei A, Ke N, Wang Y, Tang J, He S, Hu W, Liu X. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy. Oncotarget 2017; 8(64):107500.
- Jiang Y, Zhang D, Zhang T. Research progress on the role of nuclear factor κB (NF-κB) signaling pathway in inflammation and tumor. Chine J Cell Mol Immuno 2018; 34 (12): 78 -83.
- Jin Xiaohan, Jia Yongsheng, Wu Zhongsheng. The role of nuclear factor κB in tamoxifen resistance of breast cancer. Tumor, 2018; 38 (7): 662-669.
References
Zhang Jianfeng, Liu Yunxia. New advances in chemotherapy for osteosarcoma. Zhejiang Clinic Med J 2018; 20 (8): 1464-1466.
Chen Jinquan, Zhang. Research progress on the mechanisms of chemotherapy resistance of osteosarcoma. Chin J Bone Tumor Bone Dis 2017; 6 (12): 918-923.
Yong Lei, Liu Xiaoguang. Research progress on the mechanism of osteosarcoma tolerance to cisplatin. Chin J Bone Tumor Bone Dis 2019, 8 (5): 41-46.
Liu Yishu, Qu Guofan. Research progress on long-chain non-coding RNA in osteosarcoma. Pract Oncol J 2019; 23 (3): 266-270.
Zhang J, Li XY, Hu P, Ding YS. LncRNA NORAD contributes to colorectal cancer progression by inhibition of miR-202-5p. Oncology Research Featuring Preclinic Clinic Cancer Therapeutic 2018; 26(9):1411-8.
Zhou K, Ou Q, Wang G, Zhang W, Hao Y, Li W. High long non-coding RNA NORAD expression predicts poor prognosis and promotes breast cancer progression by regulating TGF-β pathway. Cancer Cell Int 2019;19(1):63.
Gui Peng. Research progress on MiRNA's targeted regulation of drug resistance mechanism of osteosarcoma. Chin Cancer 2019; 28 (9): 694-698.
Chen R, Li X, He B, Hu W. MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma. Mol Med Rep 2017; 15(3): 1326-1334.
Zhao Zhenling, Shao Huanjun, Hao Lina. Effect of miR-410-3p on prostate cancer cell proliferation and apoptosis and its mechanism of action. Int J Urology Nephrol 2018; 38 (5): 754-758.
Bai Guangjian, Han Zhitao, Liu Ge. Research progress on osteosarcoma related lncRNA. Chin J Clinic Oncology 2018; 45 (6): 297-300.
Li Yuchun. Effect of long non-coding RNA H19 on cisplatin chemotherapy sensitivity of osteosarcoma and its mechanism of action. Chin J Gerontolog 2017; 37 (24): 6043-6046.
Huo H, Tian J, Wang R, Li Y, Qu C, Wang N. Long non-coding RNA NORAD upregulate SIP1 expression to promote cell proliferation and invasion in cervical cancer. Biomed Pharmac. 2018; 106:1454-60.
Li H, Wang X, Wen C, Huo Z, Wang W, Zhan Q, Cheng D, Chen H, Deng X, Peng C, Shen B. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. Mol Cancer 2017; 16(1):169.
Tan BS, Yang MC, Singh S, Chou YC, Chen HY, Wang MY, Wang YC, Chen RH. LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. Oncogene 2019; 38(28): 5612-26.
Wang C, Huang S, Rao S, Hu J, Zhang Y, Luo J, Wang H. Decreased expression of miR-410-3p correlates with poor prognosis and tumorigenesis in human glioma. Cancer Manag Res, 2019; 11(1): 10581-10592.
Zhang YF, Yu Y, Song WZ, Zhang RM, Jin S, Bai JW, Kang HB, Wang X, Cao XC. miR-410-3p suppresses breast cancer progression by targeting Snail. Oncol Rep, 2016; 36(1): 480-486.
Zhang L, Pang Y, Cui X, Jia W, Cui W, Liu Y, Liu C, Li F. MicroRNA-410-3p upregulation suppresses proliferation, invasion and migration, and promotes apoptosis in rhabdomyosarcoma cells. Oncol Lett, 2019, 18(1): 936-943.
Xiong J, Wang D, Wei A, Ke N, Wang Y, Tang J, He S, Hu W, Liu X. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy. Oncotarget 2017; 8(64):107500.
Jiang Y, Zhang D, Zhang T. Research progress on the role of nuclear factor κB (NF-κB) signaling pathway in inflammation and tumor. Chine J Cell Mol Immuno 2018; 34 (12): 78 -83.
Jin Xiaohan, Jia Yongsheng, Wu Zhongsheng. The role of nuclear factor κB in tamoxifen resistance of breast cancer. Tumor, 2018; 38 (7): 662-669.